FGF21, fibroblast growth factor 21, 26291

N. diseases: 236; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Association of OSAHS Hypoxia Indicators with Early Renal Injury and Serum Fibroblast Growth Factor 21 in Obese Type 2 Diabetic Patients. 31172456 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Collectively, the results of the present study revealed a new mechanism underlying the regulation of hepatic ER stress and FGF21 expression induced by EPO; thus, EPO may be considered as a potential therapeutic agent for the treatment of fatty liver and obesity. 31173165 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Elevated levels of FGF21 and decreased levels of adiponectin in obesity indicate FGF21-adiponectin axis dysfunction. 30978696 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver. 30520566 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Among those browning agents reported recently, FGF21 play as a quite promising candidate for treating obesity for its obvious enhancement of thermogenic capacity in adipocyte and significant improvement of metabolic disorders in both mice and human. 30496126 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Previous studies showed that FGF21 ameliorated and prevented the development of metabolic disorders, such as obesity and diabetes mellitus. 30991048 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE This review will cover the complexities in FGF21 biology in rodents and humans, with emphasis on its role in protection from central and peripheral facets of obesity. 31248786 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE In this study, we investigated the effects of FGF21 deficiency on obesity-induced hypothalamic inflammation and thermogenic responses. 30863887 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Our data indicate that glucolipotoxicity-induced FGF21 activation mediates islet autophagy via AMPK inhibition, and further consolidate the evidence for the FGF21/analog being a pharmacotherapeutic target for obesity and its related T2DM. 31121855 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE However, plasma FGF21 levels are paradoxically increased in type 2 diabetes mellitus (T2DM) and obesity, suggesting resistance to this ligand. 31798902 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE In this study, we investigated the effect of FGF21 deficiency on obesity-induced skeletal muscle inflammation and atrophy in mice. 31312114 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Results The T allele of rs11665896 in the FGF21 gene was associated with obesity (odds ratio [OR] = 1.99, 95% confidence interval [CI] = 1.14-3.46; p = 0.0151). 31323006 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Furthermore, treatment with FGF21 could obviously reverse NAFLD and synergistically alleviate obesity and counteract insulin resistance. 31419414 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Besides, serum levels of FGF21 increase in various diseases including in diabetes mellitus, hypertension, and obesity, which may be related to initiating and exacerbating atherosclerosis. 30879171 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE In this review we focus on circulating FGF21 levels in humans and their associations with disease and clinical parameters, focusing primarily on obesity and obesity-associated diseases such as type-2 diabetes. 31108554 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Cross-sectional associations were observed between IHTG and IGF1 (β = -0.51; 95% CI, -0.82 to -0.20), IGFBP1 (β = -4.2; 95% CI, -7.7 to -0.7), and FGF21 (β = 2.1; 95% CI, 1.3 to 2.9) in lean men and men with abdominal obesity combined. 30753672 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE In humans, circulating FGF21 levels are increased in insulin-resistant morbidities such as obesity and type 2 diabetes mellitus (T2DM). 30346647 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. 30848827 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE The data demonstrate an important AHR-FGF21 regulatory axis that influences adipose biology and may represent a "druggable" therapeutic target for obesity and its related metabolic disorders. 30813227 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH. 30893110 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Maresin 1 Regulates Hepatic FGF21 in Diet-Induced Obese Mice and in Cultured Hepatocytes. 31576649 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE In recent clinical trials, an FGF21 analogue reduced insulin levels and body weight, and ameliorated dyslipidemia in patients with type 2 diabetes mellitus and obesity, all of which are well-known risk factors for kidney disease. 29108880 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Results obtained by ELISA and real-time polymerase chain reaction showed that FGF-21 efficiently ameliorated obesity-related inflammation in MSG-obesity mice. 30703283 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE The Fibroblast Growth Factor 21 (FGF21) is considered an attractive therapeutic target for obesity and obesity-related disorders due to its beneficial effects in lipid and carbohydrate metabolism. 31546675 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Serum FGF21 levels were significantly higher in obesity and type 2 diabetes mellitus (T2DM) populations. 31582974 2019